- Home
- HASI vs FOLD Comparison
HASI vs FOLD Comparison
Compare HASI & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HASI | FOLD |
|---|---|---|
| Founded | 1981 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.5B |
| IPO Year | 2012 | 2006 |
Fundamental Metrics
Financial Performance| Metric | HASI | FOLD |
|---|---|---|
| Price | $37.36 | $14.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $42.38 | $27.25 |
| AVG Volume (30 Days) | 743.5K | ★ 2.9M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.63% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $400,502,000.00 | N/A |
| Revenue This Year | $61.10 | $20.50 |
| Revenue Next Year | $250.69 | $18.59 |
| P/E Ratio | $26.06 | ★ N/A |
| Revenue Growth | ★ 4.41 | N/A |
| 52 Week Low | $21.98 | $5.66 |
| 52 Week High | $40.01 | $14.46 |
Technical Indicators
Market Signals| Indicator | HASI | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 58.07 | 73.82 |
| Support Level | $35.18 | $14.21 |
| Resistance Level | $40.01 | N/A |
| Average True Range (ATR) | 1.02 | 0.02 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 94.29 | 94.44 |
Price Performance
Historical ComparisonAbout HASI Hannon Armstrong Sustainable Infrastructure Capital Inc.
HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.